Drug profile · INN
ubrogepant
UBRELVY
ubrogepant (UBRELVY) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — ubrogepant
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ubrogepant (UBRELVY) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Calcitonin gene-related peptide type 1 receptor antagonist
Primary target: Calcitonin gene-related peptide type 1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ubrogepant?
ubrogepant (UBRELVY) is a calcitonin gene-related peptide type 1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ubrogepant?
UBRELVY is a marketed brand name for ubrogepant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ubrogepant?
ubrogepant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.